$0.7472
-0.0138-1.81%
Last update: Oct 26, 5:51 PM
Compass Therapeutics Inc (CMPX) Stock Price, Quote, News & History
CMPXNASDAQ
Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.
You can purchase shares of Compass Therapeutics (NASDAQ:CMPX) through any online brokerage.
Other companies in Compass Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Compass Therapeutics has a consensus price target of $8.57.
The stock price for Compass Therapeutics (NASDAQ: CMPX) is $0.7481 last updated October 26, 2026 at 5:51 PM EDT.
There are no upcoming dividends for Compass Therapeutics.
Compass Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Compass Therapeutics.
Compass Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the...
